JPWO2020011724A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020011724A5 JPWO2020011724A5 JP2021500279A JP2021500279A JPWO2020011724A5 JP WO2020011724 A5 JPWO2020011724 A5 JP WO2020011724A5 JP 2021500279 A JP2021500279 A JP 2021500279A JP 2021500279 A JP2021500279 A JP 2021500279A JP WO2020011724 A5 JPWO2020011724 A5 JP WO2020011724A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- alkyl
- pharmaceutical composition
- cancer
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 125000005843 halogen group Chemical group 0.000 claims description 15
- 125000003342 alkenyl group Chemical group 0.000 claims description 12
- 108090001123 antibodies Proteins 0.000 claims description 9
- 102000004965 antibodies Human genes 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 241000658540 Ora Species 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 125000001544 thienyl group Chemical group 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 125000005907 alkyl ester group Chemical group 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 4
- 125000005647 linker group Chemical group 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- 125000005466 alkylenyl group Chemical group 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- IBAHLNWTOIHLKE-UHFFFAOYSA-N cyano cyanate Chemical compound N#COC#N IBAHLNWTOIHLKE-UHFFFAOYSA-N 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 150000002825 nitriles Chemical group 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 150000001768 cations Chemical class 0.000 claims description 2
- 125000005842 heteroatoms Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000000611 antibody drug conjugate Substances 0.000 claims 11
- 108091008116 antibody drug conjugates Proteins 0.000 claims 11
- 102100006815 IL2RA Human genes 0.000 claims 8
- 101700082799 IL2RA Proteins 0.000 claims 8
- 101700015336 ISG20 Proteins 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 229960005277 gemcitabine Drugs 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 206010024324 Leukaemias Diseases 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 206010025310 Other lymphomas Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 125000006593 (C2-C3) alkynyl group Chemical group 0.000 claims 2
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 2
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 2
- 208000006557 Lymphoma, B-Cell, Marginal Zone Diseases 0.000 claims 2
- 206010026798 Mantle cell lymphomas Diseases 0.000 claims 2
- 210000004214 Philadelphia Chromosome Anatomy 0.000 claims 2
- 210000004027 cells Anatomy 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 210000002768 hair cell Anatomy 0.000 claims 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 229920002574 CR-39 Polymers 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 206010020243 Hodgkin's disease Diseases 0.000 claims 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims 1
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 239000000562 conjugate Substances 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 201000008325 diseases of cellular proliferation Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 200000000028 growth disorder Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 201000006439 lymphocytic leukemia Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000004882 non-tumor cells Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 230000002062 proliferating Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000000306 recurrent Effects 0.000 claims 1
- 108060005723 speA Proteins 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000004083 survival Effects 0.000 claims 1
- 210000004881 tumor cells Anatomy 0.000 claims 1
Description
(if)
(If)
からなる群から選択され;
C2’とC3’の間に単結合がある場合、
R12は、以下の:
Selected from the group consisting of;
If there is a single bond between C2'and C3'
R12 is as follows:
R6及びR9は、独立して、H、R、OH、OR、SH、SR、NH2、NHR、NRR’、ニトロ、Me3Sn及びハロから選択され;
ここで、R及びR’は、独立して、場合によっては、置換されたC1~12アルキル、C3~20ヘテロシクリル及びC5~20アリール基から選択され;
R7は、H、R、OH、OR、SH、SR、NH2、NHR、NRR’、ニトロ、Me3Sn及びハロから選択され;
R”は、C 3~12 アルキレン基であり、その鎖は、1又はそれ以上のヘテロ原子、例えばO、S、NRN2(ここで、RN2は、H又はC1~4アルキルである)、及び/又は芳香環、例えばベンゼン又はピリジンにより中断されてよく;
Y、及びY’は、O、S又はNHから選択され;
R6’、R7’、R9’は各々、前記R6、R7及びR9と同じ基から選択され;
[式I]において
RL1’は、当該抗体(Ab)に結合するリンカーであり;
R11aは、OH、ORAであって前記RAはC1~4アルキルであり、及びSOzM(式中、zは2又は3であり、Mは一価の医薬的に許容されるカチオンである)から選択され;
R20とR21はともに、それらが結合する窒素原子と炭素原子の間に二重結合を形成するか又は;
R20は、H及びRCから選択され、ここでRCはキャッピング基であり;
R21は、OH、ORA及びSOzMから選択され;
C2とC3の間に二重結合がある場合、R2は、以下の:
(ia)場合によっては、ハロ、ニトロ、シアノ、エーテル、カルボキシ、エステル、C1~7アルキル、C3~7ヘテロシクリル及びビス-オキシ-C1~3アルキレンを含む群から選択される、1又はそれ以上の置換基により置換されるC5~10アリール基;
(ib)C1~5飽和脂肪族アルキル;
(ic)C3~6飽和シクロアルキル;
(id)
R 6 and R 9 are independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR', nitro, Me 3 Sn and halo;
Here, R and R'are independently selected from substituted C 1-12 alkyl, C 3-20 heterocyclyl and C 5-20 aryl groups;
R 7 is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR', nitro, Me 3 Sn and halo;
"R" is a C 3-12 alkylene group, the chain of which is one or more heteroatoms such as O, S, NR N2 (where RN2 is H or C 1-4 alkyl). And / or may be interrupted by an aromatic ring, such as benzene or pyridine;
Y and Y'are selected from O, S or NH;
R 6' , R 7' , and R 9'are selected from the same groups as R 6 , R 7 and R 9 , respectively ;
In [Formula I], RL1'is a linker that binds to the antibody (Ab);
R 11a is OH, ORA, said RA is C 1-4 alkyl, and SOzM (where z is 2 or 3 in the formula, M is a monovalent pharmaceutically acceptable cation). Selected from ) ;
Both R 20 and R 21 form a double bond between the nitrogen and carbon atoms to which they bond, or ;
R 20 is selected from H and RC , where RC is the capping group;
R 21 is selected from OH, ORA and SOzM ;
If there is a double bond between C2 and C3, then R2 is:
(IA) In some cases selected from the group comprising halo, nitro, cyano, ether, carboxy, ester, C 1-7 alkyl, C 3-7 heterocyclyl and bis-oxy-C 1-3 alkylene, 1 or C 5-10 aryl groups substituted with more substituents;
(Ib) C 1-5 saturated aliphatic alkyl;
(Ic) C 3-6 saturated cycloalkyl;
(Id)
(if)
(If)
からなる群から選択され;
C2とC3の間に単結合がある場合、
R2は、
Selected from the group consisting of;
If there is a single bond between C2 and C3
R 2 is
RL2’は、抗体(Ab)に結合するリンカーであり;
R10
及びR11はともに、それらと結合している窒素原子と炭素原子との間に二重結合を形成するか又は;
R10はHであり、R11はOH、ORA及びSOzMから選択され;
R30及びR31はともに、それらが結合している窒素原子と炭素原子との間に二
重結合を形成するか又は、又は;
R30はHであり、R31はOH、ORA及びSOzMから選択される)である。
RL2'is a linker that binds to antibody (Ab);
Both R 10 and R 11 form a double bond between the nitrogen and carbon atoms attached to them, or;
R 10 is H and R 11 is selected from OH, ORA and SOzM ;
Both R 30 and R 31 form a double bond between the nitrogen and carbon atoms to which they are bonded, or;
R 30 is H and R 31 is selected from OH, ORA and SOzM ).
Claims (15)
ここで、前記抗CD25 ADCは、CD25に結合する抗体とピロロベンゾジアゼピン(PBD)弾頭とを含み、場合によっては、前記PBD弾頭はPBD二量体を含む、医薬組成物。 A pharmaceutical composition comprising an anti-CD25 antibody drug conjugate (ADC) (anti-CD25 ADC) for treating growth disorders in an individual, wherein the treatment comprises an effective amount of the anti-CD25 ADC and gemcitabine in the individual. Including administration
Here, the anti-CD25 ADC comprises an antibody that binds to CD25 and a pyrolobenzodiazepine (PBD) warhead, and in some cases, the PBD warhead comprises a PBD dimer .
Lは、CD25に結合する抗体である抗体(Ab)であり;
C2’とC3’の間に二重結合がある場合、R 12 は、以下の:
(ia)場合によっては、ハロ、ニトロ、シアノ、エーテル、カルボキシ、エステル、C 1~7 アルキル、C 3~7 ヘテロシクリル及びビス-オキシ-C 1~3 アルキレンを含む群から選択される、1又はそれ以上の置換基により置換されるC 5~10 アリール基;
(ib)C 1~5 飽和脂肪族アルキル;
(ic)C 3~6 飽和シクロアルキル;
(id)
(ie)
(if)
からなる群から選択され;
C2’とC3’の間に単結合がある場合、
R 12 は、以下の:
R 6 及びR 9 は、独立して、H、R、OH、OR、SH、SR、NH 2 、NHR、NRR’、ニトロ、Me 3 Sn及びハロから選択され;
ここで、R及びR’は、独立して、場合によっては、置換されたC 1~12 アルキル、C 3~20 ヘテロシクリル及びC 5~20 アリール基から選択され;
R 7 は、H、R、OH、OR、SH、SR、NH 2 、NHR、NRR’、ニトロ、Me 3 Sn及びハロから選択され;
R”は、C 3~12 アルキレン基であり、その鎖は、1又はそれ以上のヘテロ原子、例えばO、S、NR N2 (ここで、R N2 は、H又はC 1~4 アルキルである)、及び/又は芳香環、例えばベンゼン又はピリジンにより中断されてよく;
Y及びY’は、O、S又はNHから選択され;
R 6’ 、R 7’ 、R 9’ は各々、前記R 6 、R 7 及びR 9 と同じ基から選択され;
[式I]において
R L1’ は、前記抗体(Ab)に結合するリンカーであり;
R 11a は、OH、OR A であって前記R A はC 1~4 アルキル、及びSOzM(式中、zは2又は3であり、Mは一価の医薬的に許容されるカチオンである)、から選択され;
R 20 とR 21 はともに、それらが結合する窒素原子と炭素原子の間に二重結合を形成するか又は;
R 20 は、H及びR C から選択され、ここでR C はキャッピング基であり;
R 21 は、OH、OR A 及びSOzMから選択され;
C2とC3の間に二重結合がある場合、R 2 は、以下の:
(ia)場合によっては、ハロ、ニトロ、シアノ、エーテル、カルボキシ、エステル、C 1~7 アルキル、C 3~7 ヘテロシクリル及びビス-オキシ-C 1~3 アルキレンを含む群から選択される、1又はそれ以上の置換基により置換されるC 5~10 アリール基;
(ib)C 1~5 飽和脂肪族アルキル;
(ic)C 3~6 飽和シクロアルキル;
(id)
(ie)
(if)
からなる群から選択され;
C2とC3の間に単結合がある場合、
R 2 は、
〔式II〕において、
R 22 は、以下の式IIIa、式IIIb又は式IIIcであり:
(a)
(i)Q 1 は単結合であり、かつ、Q 2 は単結合及び-Z-(CH 2 ) n -から選択され、ここで、前記Zは、単結合、O、S及びNHから選択され、nは1~3である;か又は、
(ii)Q 1 は-CH=CH-、かつ、Q2は単結合である;のいずれかである);
(b)
(c)
Xは、O-R L2’ 、S-R L2’ 、CO 2 -R L2’ 、CO-R L2’ 、NH-C(=O)-R L2’ 、NHNH-R L2’ 、CONHNH-R L2’ 、
R L2’ は、抗体(Ab)に結合するリンカーであり;
R 10 及びR 11 はともに、それらと結合している窒素原子と炭素原子との間に二重結合を形成するか又は;
R 10 はHであり、R 11 はOH、OR A 及びSOzMから選択され;
R 30 及びR 31 はともに、それらが結合している窒素原子と炭素原子との間に二重結合を形成するか又は、又は;
R 30 はHであり、R 31 はOH、OR A 及びSOzMから選択される)
で表される、請求項1に記載の医薬組成物。 The anti-CD25 ADC is a conjugate of the formula L- (DL) p, where the DL is the following formula I or II :.
L is an antibody (Ab) that is an antibody that binds to CD25;
If there is a double bond between C2'and C3', then R 12 is:
(IA) In some cases selected from the group comprising halo, nitro, cyano, ether, carboxy, ester, C 1-7 alkyl, C 3-7 heterocyclyl and bis-oxy-C 1-3 alkylene, 1 or C 5-10 aryl groups substituted with more substituents ;
(Ib) C 1-5 saturated aliphatic alkyl;
(Ic) C 3-6 saturated cycloalkyl;
(Id)
(IE)
(If)
Selected from the group consisting of;
If there is a single bond between C2'and C3'
R12 is as follows :
R 6 and R 9 are independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR', nitro, Me 3 Sn and halo;
Here, R and R'are independently selected from substituted C 1-12 alkyl, C 3-20 heterocyclyl and C 5-20 aryl groups;
R 7 is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR', nitro, Me 3 Sn and halo;
"R" is a C 3-12 alkylene group, the chain of which is one or more heteroatoms such as O, S, NR N2 (where RN2 is H or C 1-4 alkyl). And / or may be interrupted by an aromatic ring, such as benzene or pyridine;
Y and Y'are selected from O, S or NH;
R 6' , R 7' , and R 9'are selected from the same groups as R 6 , R 7 and R 9 , respectively ;
In [Equation I]
RL1'is a linker that binds to the antibody (Ab) ;
R 11a is OH, ORA, said RA is C 1-4 alkyl , and SOzM (where z is 2 or 3 in the formula, M is a monovalent pharmaceutically acceptable cation). , Selected from;
Both R 20 and R 21 form a double bond between the nitrogen and carbon atoms to which they bond, or;
R 20 is selected from H and RC , where RC is the capping group;
R 21 is selected from OH, ORA and SOzM ;
If there is a double bond between C2 and C3, then R2 is :
(IA) In some cases selected from the group comprising halo, nitro, cyano, ether, carboxy, ester, C 1-7 alkyl, C 3-7 heterocyclyl and bis-oxy-C 1-3 alkylene, 1 or C 5-10 aryl groups substituted with more substituents ;
(Ib) C 1-5 saturated aliphatic alkyl;
(Ic) C 3-6 saturated cycloalkyl;
(Id)
(IE)
(If)
Selected from the group consisting of;
If there is a single bond between C2 and C3
R 2 is
In [Formula II]
R 22 is the following formula IIIa, formula IIIb or formula IIIc:
(A)
(I) Q 1 is a single bond and Q 2 is selected from a single bond and —Z— (CH 2 ) n −, where Z is selected from a single bond, O, S and NH. , N are 1-3; or
(Ii) Q1 is -CH = CH- and Q2 is a single bond;
(B)
(C)
X is O-R L2' , S-R L2' , CO2 - R L2 ' , CO-R L2' , NH-C (= O) -R L2' , NHNH-R L2' , CONHNH-R L2 . ' ,,
RL2'is a linker that binds to antibody (Ab) ;
Both R 10 and R 11 form a double bond between the nitrogen and carbon atoms attached to them, or;
R 10 is H and R 11 is selected from OH, ORA and SOzM ;
Both R 30 and R 31 form a double bond between the nitrogen and carbon atoms to which they are bonded, or;
R 30 is H and R 31 is selected from OH, ORA and SOzM )
The pharmaceutical composition according to claim 1.
である化学構造がある、請求項1又は2に記載の医薬組成物。The pharmaceutical composition according to claim 1 or 2, which has a chemical structure thereof.
(i)配列番号3のアミノ酸配列で表されるVH CDR1、配列番号4のアミノ酸配列で表されるVH CDR2、及び配列番号5のアミノ酸配列で表されるVH CDR3を含むVHドメイン。(I) A VH domain comprising VH CDR1 represented by the amino acid sequence of SEQ ID NO: 3, VH CDR2 represented by the amino acid sequence of SEQ ID NO: 4, and VH CDR3 represented by the amino acid sequence of SEQ ID NO: 5.
(ii)配列番号1で表されるVHドメイン。(Ii) The VH domain represented by SEQ ID NO: 1.
(iii)配列番号6のアミノ酸配列で表されるVL CDR1、配列番号7のアミノ酸配列で表されるVL CDR2、及び配列番号8のアミノ酸配列で表されるVL CDR3;及び/又は(Iii) VL CDR1 represented by the amino acid sequence of SEQ ID NO: 6, VL CDR2 represented by the amino acid sequence of SEQ ID NO: 7, and VL CDR3 represented by the amino acid sequence of SEQ ID NO: 8; and / or
(iv)配列番号2による配列で表されるVLドメイン;(Iv) VL domain represented by the sequence according to SEQ ID NO: 2.
を備える、抗体を含む、請求項1~3のいずれか一項に記載の医薬組成物。The pharmaceutical composition according to any one of claims 1 to 3, comprising an antibody.
(i)増殖性障害があるか又はあると決定されている;(I) Proliferative disorders are or have been determined to be present;
(ii)CD25+ve細胞及びCD25-ve細胞をともに含む新生物の存在により特徴付けられるがんであるか、又はであったと決定されている;(Ii) It has been determined that the cancer was or was characterized by the presence of neoplasms containing both CD25 + ve cells and CD25-ve cells;
(iiiCD25-ve腫瘍細胞を含む、又はで構成される新生物の存在を特徴とするがんであるか、又はであったと決定されている;It has been determined that the cancer was or was characterized by the presence of neoplasms containing or composed of iiiCD25-ve tumor cells;
請求項1~8のいずれか一項に記載の医薬組成物。The pharmaceutical composition according to any one of claims 1 to 8.
(iv)CD25又はCD25+腫瘍関連非腫瘍細胞、例えば、CD25+浸潤性T細胞を発現するがんであるか、又はであったと決定されている;(Iv) It has been determined that the cancer was or was expressing CD25 or CD25 + tumor-related non-tumor cells, such as CD25 + invasive T cells;
(v)CD25の表面発現が低レベルで発現するがんであるか、又はであったと決定されている;(V) It has been determined that the surface expression of CD25 was or was a cancer expressed at low levels;
(vi)第2標的タンパク質を発現するがんであるか、又はであったと決定されている;(Vi) It has been determined that the cancer expressed or was a second target protein;
請求項1~10のいずれか一項に記載の医薬組成物。The pharmaceutical composition according to any one of claims 1 to 10.
a)より広範な疾患を効果的に治療し;a) Effectively treat a wider range of diseases;
b)抵抗性、難治性、又は再発性の疾患を効果的に治療し;b) Effectively treat resistant, refractory, or recurrent disease;
c)奏効率が高く;及び/又は、c) High response rate; and / or
d)生存率が向上する;d) Improves survival;
請求項1~11のいずれか一項に記載の医薬組成物。The pharmaceutical composition according to any one of claims 1 to 11.
びまん性大細胞型B細胞リンパ腫(DLBCL)、濾胞性リンパ腫(FL)、マントル細胞リンパ腫(MCL)、慢性リンパ腫(CLL)、辺縁帯B細胞リンパ腫(MZBL)を含む、ホジキンリンパ腫、及び非ホジキンリンパ腫;Hodgkin's lymphoma, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphoma (CLL), marginal zone B-cell lymphoma (MZBL), and non-Hodgkin. Lymphoma;
有毛細胞白血病(HCL)、有毛細胞白血病変異型(HCL-v)、急性骨髄性白血病(AML)、フィラデルフィア染色体陽性ALL(Ph+ALL)又はフィラデルフィア染色体陰性ALL(Ph-ALL)等の急性リンパ芽球性白血病(ALL)等の白血病;Acute such as hair cell leukemia (HCL), hair cell leukemia variant (HCL-v), acute myeloid leukemia (AML), Philadelphia chromosome positive ALL (Ph + ALL) or Philadelphia chromosome negative ALL (Ph-ALL). Leukemia such as lymphoblastic leukemia (ALL);
膵がん、乳がん、大腸がん、胃がん及び食道がん、白血病及びリンパ腫、黒色腫、非小細胞肺がん、卵巣がん、肝細胞がん、腎細胞がん並びに頭頸部がん。Pancreatic cancer, breast cancer, colon cancer, gastric cancer and esophageal cancer, leukemia and lymphoma, melanoma, non-small cell lung cancer, ovarian cancer, hepatocellular cancer, renal cell cancer and head and neck cancer.
を含む、群から選択される、請求項1~12のいずれか一項に記載の医薬組成物。The pharmaceutical composition according to any one of claims 1 to 12, which is selected from the group.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1811364.7A GB201811364D0 (en) | 2018-07-11 | 2018-07-11 | Combination therapy |
GB1811364.7 | 2018-07-11 | ||
PCT/EP2019/068287 WO2020011724A1 (en) | 2018-07-11 | 2019-07-08 | Combination therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021533090A JP2021533090A (en) | 2021-12-02 |
JPWO2020011724A5 true JPWO2020011724A5 (en) | 2022-07-19 |
Family
ID=63272970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021500279A Pending JP2021533090A (en) | 2018-07-11 | 2019-07-08 | Combination therapy |
Country Status (16)
Country | Link |
---|---|
US (1) | US20230132256A1 (en) |
EP (1) | EP3820478A1 (en) |
JP (1) | JP2021533090A (en) |
KR (1) | KR20210031696A (en) |
CN (1) | CN112367999A (en) |
AU (1) | AU2019301850A1 (en) |
BR (1) | BR112021000456A2 (en) |
CA (1) | CA3101703A1 (en) |
EA (1) | EA202092824A1 (en) |
GB (1) | GB201811364D0 (en) |
IL (1) | IL279908A (en) |
MX (1) | MX2020013446A (en) |
PH (1) | PH12021550035A1 (en) |
SG (1) | SG11202012401RA (en) |
UA (1) | UA126313C2 (en) |
WO (1) | WO2020011724A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
GB202015916D0 (en) * | 2020-10-07 | 2020-11-18 | Adc Therapeutics Sa | Combination therapy |
WO2022248268A1 (en) * | 2021-05-28 | 2022-12-01 | Adc Therapeutics Sa | Combination therapy |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT60768A (en) | 1990-03-16 | 1992-10-28 | Sandoz Ag | Process for producing cd25 fixing molecules |
ES2401136T3 (en) | 2002-11-15 | 2013-04-17 | Genmab A/S | Human monoclonal antibodies against CD25 |
CA2927656C (en) | 2005-10-07 | 2019-09-24 | Exelixis, Inc. | Mek inhibitors and methods of their use |
ES2653617T3 (en) * | 2011-02-02 | 2018-02-08 | Ashland Licensing And Intellectual Property, Llc | Scratch resistant gel coating |
EP2906250B1 (en) * | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
CN105102068B (en) | 2012-10-12 | 2018-06-01 | Adc疗法责任有限公司 | Pyrrolobenzodiazepines Zhuo-antibody conjugates |
US10780096B2 (en) | 2014-11-25 | 2020-09-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
GB201506405D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201507827D0 (en) * | 2015-05-07 | 2015-06-17 | Adc Therapeutics Sarl | Diagnostic test |
-
2018
- 2018-07-11 GB GBGB1811364.7A patent/GB201811364D0/en not_active Ceased
-
2019
- 2019-07-08 JP JP2021500279A patent/JP2021533090A/en active Pending
- 2019-07-08 CA CA3101703A patent/CA3101703A1/en active Pending
- 2019-07-08 KR KR1020217001943A patent/KR20210031696A/en unknown
- 2019-07-08 EP EP19742541.6A patent/EP3820478A1/en active Pending
- 2019-07-08 EA EA202092824A patent/EA202092824A1/en unknown
- 2019-07-08 CN CN201980045650.9A patent/CN112367999A/en active Pending
- 2019-07-08 MX MX2020013446A patent/MX2020013446A/en unknown
- 2019-07-08 SG SG11202012401RA patent/SG11202012401RA/en unknown
- 2019-07-08 US US17/259,466 patent/US20230132256A1/en active Pending
- 2019-07-08 AU AU2019301850A patent/AU2019301850A1/en not_active Abandoned
- 2019-07-08 BR BR112021000456-4A patent/BR112021000456A2/en not_active Application Discontinuation
- 2019-07-08 UA UAA202008232A patent/UA126313C2/en unknown
- 2019-07-08 WO PCT/EP2019/068287 patent/WO2020011724A1/en active Application Filing
-
2020
- 2020-12-31 IL IL279908A patent/IL279908A/en unknown
-
2021
- 2021-01-06 PH PH12021550035A patent/PH12021550035A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019518741A5 (en) | ||
ES2400070T3 (en) | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for the treatment of human cancers | |
JP2018502902A5 (en) | ||
TW202218685A (en) | Anti-her3 antibody drug conjugate, and medicine and pharmaceutical composition containing the same | |
JP6557744B2 (en) | Antitumor agent and antitumor effect potentiator | |
ES2808565T3 (en) | Compositions comprising anti-CD38 antibodies and carfilzomib | |
JP2018516243A5 (en) | ||
JP2017515802A5 (en) | ||
US20200297693A1 (en) | Glucose conjugates of triptolide, analogs and uses thereof | |
JP2018511628A5 (en) | ||
JP2021059564A (en) | Combination therapy for cancer treatment | |
ES2660215T3 (en) | Antitumor effect enhancer comprising an imidazooxazine compound | |
JP6002835B2 (en) | Antitumor agent containing low-dose irinotecan hydrochloride hydrate | |
WO2020122034A1 (en) | Combination of antibody-drug conjugate with parp inhibitor | |
JP2018531278A6 (en) | Combination therapy for cancer | |
JP2018531278A (en) | Combination therapy for cancer | |
JP2021169511A (en) | Combination compositions for immunotherapy | |
KR20080048489A (en) | Novel anticancer concomitant drug | |
JPWO2020011724A5 (en) | ||
JP2016540826A5 (en) | ||
TW201343169A (en) | Methods of treating cancer using Aurora kinase inhibitors | |
JPWO2019224275A5 (en) | ||
JP7479292B2 (en) | Pharmaceutical compositions containing EZH1/2 dual inhibitors for use as combination medicines | |
KR20210142700A (en) | anti-tumor composition | |
JP7154634B2 (en) | Tumor immunostimulant |